Like astaxanthin, it was found that metformin (used as a first-line therapy for type 2 diabetes mellitus) can decrease the cellular level of NF-κB which leads to decreasing the cellular levels of TNF-α, IL-1β, and IL-6 [69]. Here, IL6 is linked to type 2 diabetes mellitus.